Methamphetamine Dependence Clinical Trial
Official title:
Sustained-Release Methylphenidate for Management of Methamphetamine Dependence
This 4-year study will investigate the effectiveness of methylphenidate for initiating and sustaining abstinence in methamphetamine dependent individuals. Approximately 90 participants seeking treatment for methamphetamine dependence will be enrolled in the study for an initial 2 weeks to establish clinic compliance. During this compliance phase, participants will receive incentives for clinic attendance. After meeting clinic attendance requirements, participants will be randomized to placebo (n = 45) or active study medication (n = 45) conditions, and given 18mg/daily of study drug or placebo for one week, followed by 36mg/daily study drug/placebo for a second week. Finally, participants will be stabilized on 54mg/daily study drug/placebo for the remainder of the study. Placebo participants will be given placebo medications prepared to appear identical to the active medication. In addition, after randomization, all participants will receive motivational incentives for methamphetamine-negative urine tests and begin weekly cognitive behavioral therapy (CBT) provided for the duration of the study.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01813656 -
An Study of Aripiprazole in the Treatment of Methamphetamine Dependence
|
Phase 4 | |
| Completed |
NCT00984360 -
Study of Naltrexone for Methamphetamine Addiction
|
Phase 2 | |
| Completed |
NCT01685463 -
Transcranial Magnetic Stimulation Used to Both Measure Cortical Excitability and Explore Methamphetamine Cue Craving
|
N/A | |
| Completed |
NCT00569374 -
Safety and Tolerability of Modafinil for Methamphetamine Dependence
|
Phase 2 | |
| Completed |
NCT01967381 -
Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse
|
Early Phase 1 | |
| Completed |
NCT01354470 -
A Randomized, Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence
|
Phase 2 | |
| Completed |
NCT01215929 -
Studying Amphetamine Withdrawal in Humans
|
Phase 2 | |
| Terminated |
NCT01019707 -
Safety Assessment of Atomoxetine With MA IV Administration
|
Phase 1 | |
| Completed |
NCT00227123 -
A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder With Stimulant Dependence
|
N/A | |
| Recruiting |
NCT02568878 -
Creatine for Depressed Male and Female Methamphetamine Users
|
Phase 3 | |
| Completed |
NCT01011829 -
Varenicline vs Placebo for the Treatment of Methamphetamine Dependence
|
Phase 2 | |
| Completed |
NCT01007539 -
Efficacy and Safety of CDP-choline in Patients With Methamphetamine Dependence
|
Phase 3 | |
| Completed |
NCT01062451 -
An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence
|
Phase 1 | |
| Completed |
NCT00687713 -
Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence
|
Phase 2 | |
| Completed |
NCT01063205 -
NAC as a Potential Treatment for Methamphetamine Dependence
|
Phase 1 | |
| Completed |
NCT02058966 -
Pilot Study of Entacapone for Methamphetamine Abuse
|
Early Phase 1 | |
| Completed |
NCT00332605 -
N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence
|
Phase 2 | |
| Completed |
NCT01860807 -
Trial of Ibudilast for Methamphetamine Dependence
|
Phase 2 | |
| Terminated |
NCT01813643 -
A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis
|
Phase 4 | |
| Completed |
NCT01073319 -
Rivastigmine as a Treatment for Methamphetamine Dependence
|
Phase 1 |